Last reviewed · How we verify
Investigational live attenuated varicella vaccine
The investigational live attenuated varicella vaccine, developed by Sinovac (Dalian) Vaccine Technology Co., Ltd., is currently marketed but lacks detailed revenue figures. A key strength is the protection of its core composition through a patent expiring in 2028. The primary risk is the lack of disclosed key trial results and competitor information, which may impact market confidence and positioning.
At a glance
| Generic name | Investigational live attenuated varicella vaccine |
|---|---|
| Sponsor | Sinovac (Dalian) Vaccine Technology Co., Ltd. |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine (PHASE1, PHASE2)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older (PHASE4)
- An Immunity Persistence Study of Live Attenuated Varicella Vaccine (PHASE4)
- An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine (PHASE4)
- Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old (PHASE3)
- Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old (PHASE3)
- A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: